Epigral Limited

rs,

oor- 25, P J Tower, Dalal Street, Mumbai 400 001 SYMBOL:- EPIGRAL Scrip Code: 543332 Dear Sirs, Sub.: Investors Presentation for Un-Audited Financial Results – Q3 FY2025 Ref.: Regulation 30 of th

11%

2025 Result update Q3FY25 - Key Highlights Q3FY25 Operational Highlights: o Sales volume grew 11% YoY, it majorly comes from Derivatives & Specialty business o Capacity utilization stood at 81% i

81%

w 11% YoY, it majorly comes from Derivatives & Specialty business o Capacity utilization stood at 81% in Q3FY25 o Realization for Caustic Soda improved in the quarter and for other products it has re

₹ 649 Crore

for other products it has remained almost same Q3FY25 Financial Highlights: o Revenue stood at ₹ 649 Crore, growth of 37% YoY on account volume growth from Derivative products o Revenue contribution from

37%

has remained almost same Q3FY25 Financial Highlights: o Revenue stood at ₹ 649 Crore, growth of 37% YoY on account volume growth from Derivative products o Revenue contribution from Derivatives & S

50%

rom Derivative products o Revenue contribution from Derivatives & Specialty business increased to 50% in Q3FY25 vs 47% in Q3FY24 o EBITDA grew by 49% to ₹ 183 Crore vs ₹ 123 Crore in Q3FY24. o EBID

47%

oducts o Revenue contribution from Derivatives & Specialty business increased to 50% in Q3FY25 vs 47% in Q3FY24 o EBITDA grew by 49% to ₹ 183 Crore vs ₹ 123 Crore in Q3FY24. o EBIDTA margin stood a

49%

rom Derivatives & Specialty business increased to 50% in Q3FY25 vs 47% in Q3FY24 o EBITDA grew by 49% to ₹ 183 Crore vs ₹ 123 Crore in Q3FY24. o EBIDTA margin stood at 28% vs 26% in Q3FY24. o PAT j

₹ 183 Crore

ivatives & Specialty business increased to 50% in Q3FY25 vs 47% in Q3FY24 o EBITDA grew by 49% to ₹ 183 Crore vs ₹ 123 Crore in Q3FY24. o EBIDTA margin stood at 28% vs 26% in Q3FY24. o PAT jumped by 110% t

₹ 123 Crore

ialty business increased to 50% in Q3FY25 vs 47% in Q3FY24 o EBITDA grew by 49% to ₹ 183 Crore vs ₹ 123 Crore in Q3FY24. o EBIDTA margin stood at 28% vs 26% in Q3FY24. o PAT jumped by 110% to ₹ 104 Crore.

28%

n Q3FY24 o EBITDA grew by 49% to ₹ 183 Crore vs ₹ 123 Crore in Q3FY24. o EBIDTA margin stood at 28% vs 26% in Q3FY24. o PAT jumped by 110% to ₹ 104 Crore. PAT margin grew to 16% vs 10% in Q3FY24

26%

4 o EBITDA grew by 49% to ₹ 183 Crore vs ₹ 123 Crore in Q3FY24. o EBIDTA margin stood at 28% vs 26% in Q3FY24. o PAT jumped by 110% to ₹ 104 Crore. PAT margin grew to 16% vs 10% in Q3FY24 o ROCE

“Responsible Care Certificate 33% 28% 4 Year Revenue CAGR (FY24) 4 Year EBITDA CAGR (FY24) 0.8x 17% Debt to Equity (FY24) ROCE (FY24) Revenue from operations (₹ Crore) 2,188 1,929 1,551 611 829”

Founded

1

Employees

1

Certified

1

Manufacturing facility

1

Integration

1

New Value Chains

1

Certified

Responsible Care Certificate 33% 28% 4 Year Revenue CAGR (FY24) 4 Year EBITDA CAGR (FY24) 0.8x 17% Debt to Equity (FY24) ROCE (FY24) Revenue from operations (₹ Crore) 2,188 1,929 1,551 611 829

Manufacturing facility

Fully-integrated & automated complex FY20 FY21 FY22 FY23 FY24 # Chlor-Alkali : Caustic Soda - 400 KTPA and Caustic Potash - 21 KTPA Derivatives : CPVC Resin – 75 KTPA, Epichlorohydrin – 50 KTPA, Chloromethanes - 50 KTPA and Hydrogen Peroxide - 60 KTPA Our Journey FY 2007 FY 2010 FY 2015 FY 2017 FY 2020 Epigral Ltd (MFL) incorporated Commissioned 1st Plant Increased capacity to Commissioned • Caustic Potash – • Caustic Soda – 167 21 KTPA • Caustic Soda – 119 KTPA KTPA • CPP – 40 MW • CPP – 60 MW Converted all Membrane to Zero Gap Commissioned • Chloromethanes – 50 KTPA Announced Capex • Epichlorohydrin – 50 KTPA FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 Commissioned • Hydrogen Peroxide – 60 KTPA Increased capacity to • Caustic Soda – 294 KTPA • CPP 96 MW Awarded “Responsible Care” Certificate Listed as an independent entity on 18th August 2021 Announced Capex • Chlorotoluene & Value Chain • Setting up R&D Centre Commissioned • Epichlorohydrin – 50 KTPA • CPVC Resin – 30 KTPA Renamed compa

Integration

o Scale up capacities in existing products o New value added products in existing value chains o Improved market position Opportunities in high growth sectors: o Explore opportunities in various sectors o Increase presence & improve market share o Entering into products which are fully imported

New Value Chains

o Expand chemistry expertise to enter new value chains (specialty chemicals) o Addition of new reaction capabilities Achieving economies of scale: o Optimising existing complex o Achieving efficiency operations to become a low cost producer Historical numbers Financial Performance – P&L Revenue from operations (₹ Crore) EBIDTA (₹ Crore and %) PAT (₹ Crore and %) 2,188 1,929 1,551 829 611 32% 32% 33% 31% 689 25% 481 509 261 194 18% 16% 16% 12% 353 253 112 101 10% 196 FY2020 FY2021 FY2022 FY2023 FY2024 FY2020 FY2021 FY2022 FY2023 FY2024 FY2020 FY2021 FY2022 FY2023 FY2024 Margin -% Balance Sheet Ratios ROCE (%)# 32% 29% ROE (%) 39% 36% Net Debt/EBITDA (x) 15% 16% 17% 21% 16% 17% 2.70 2.10 1.90 1.99 1.30 FY2020 FY2021 FY2022 FY2023 FY2024 FY2020 FY2021 FY2022 FY2023 FY2024 FY2020 FY2021 FY2022 FY2023 FY2024 #Capital employed in ROCE includes Capital Work in Progress Historic Income Statement Particulars (₹ Cr) FY20 FY21 Total Revenue Gross Profit Gross Margin (%) EBITDA EBITDA Margin (%) D